Wedbush Maintains Outperform on Elevation Oncology, Raises Price Target to $6
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Robert Driscoll maintains an Outperform rating on Elevation Oncology (NASDAQ:ELEV) and raises the price target from $4 to $6.
June 05, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll maintains an Outperform rating on Elevation Oncology and raises the price target from $4 to $6.
The news of Wedbush maintaining an Outperform rating and raising the price target for ELEV from $4 to $6 indicates a positive outlook for the stock. This could lead to increased investor interest and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100